Browse studies

Find your next paid study

125 recruiting studies matching your filters

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with adva…

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

VM Oncology, LLCNCT03556228

Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency

Succinic Semialdehyde Dehydrogenase deficiency (SSADHD) is a rare autosomal recessive disease that interferes with the catabolism of the major inhibitory neuro…

Succinic Semialdehyde Dehydrogenase Deficiency

Estimated

~$10 – $750

Actual pay is set by the research site.

Boston Children's HospitalNCT03758521

Phase 1

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astro…

Glioblastoma, IDH-wildtypeGlioblastomaGlioblastoma Multiforme+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Orbus Therapeutics, Inc.NCT05879367

Phase 3

The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literatur…

Nasolacrimal Duct ObstructionThyroid Cancer

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Vanderbilt University Medical CenterNCT05999630

Phase 1

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24…

MelanomaMedullary Thyroid CancerSinonasal Undifferentiated Carcinoma+8 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of ArizonaNCT06814496

Phase 1

An Open Label, Exploratory, Proof-of Concept Study of Triheptanoin as Treatment for Patients With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency

This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is trih…

Pyruvate Dehydrogenase Complex Deficiency

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Jirair Krikor BedoyanNCT06340685

Phase 3

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progres…

Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Nuvalent Inc.NCT06765109

PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and l…

Open SurgeryLymphedemaFree Tissue Transfer+2 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

MMI (Medical Microinstruments, Inc.)NCT06725030

Phase 3

A Multicenter, Open-label, Two-Arm, Pharmacokinetics, Safety, and Tolerability Study of a Single Topical Dose of GOPRELTO® Nasal Solution and a Single Dose of NUMBRINO™ Nasal Solution for the Induction of Local Anesthesia of the Mucous Membranes When Performing Diagnostic Procedures and Surgeries in Pediatric Subjects From ≥12 Years to <18 Years of Age

The purpose of this study is to assess the pharmacokinetic (PK) properties, safety and tolerability following a single dose administration of GOPRELTO® or NUMB…

ENT DisorderNasal ProceduresNasal Anesthesia+1 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.

LXO IrelandNCT04792034

Phase 2

A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy

The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with r…

Squamous Cell Carcinoma of Head and NeckSinus CancerNasal Cavity Cancer+9 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07063212

Observational

"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with …

Malignant Head and Neck NeoplasmMalignant NeoplasmMetastatic Malignant Neoplasm in the Neck+45 more

Multi-Institutional Validation of the Integrated Modular Patient-Reported Outcome Assessment for Craniomaxillofacial Trauma (IMPACT)

The goal of this observational study is to validate a novel patient-reported outcome measure (PROM) for patients suffering maxillofacial trauma: The Integrated…

Facial InjuriesMandible FractureLe Fort+6 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of TennesseeNCT06850857